

# **Global Renal Anemia Market Size Study, by Anemia Type (Iron Deficiency Anemia, Vitamin B12 Deficiency Anemia, Folate Deficiency Anemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia), by Treatment Type (Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation, Vitamin B12 Supplementation, Folate Supplementation, Transfusion Therapy, Bone Marrow Transplant), by Disease Severity (Mild, Moderate, Severe), by End-User (Hospitals, Dialysis Centers, Clinics, Home Healthcare), by Route of Administration (Intravenous, Subcutaneous, Oral) and Regional Forecasts 2024-2032**

<https://marketpublishers.com/r/GAA5D341B494EN.html>

Date: August 2024

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: GAA5D341B494EN

## **Abstracts**

The Global Renal Anemia Market was valued at approximately USD 2.31 Billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.05% over the forecast period from 2024 to 2032. Renal anemia is a condition characterized by a decrease in red blood cells due to chronic kidney disease (CKD). The kidneys, which normally produce erythropoietin, a hormone crucial for red blood cell production, become impaired and fail to produce enough of this hormone. As a result, patients experience symptoms such as fatigue, weakness, and pallor. Effective management often includes erythropoiesis-stimulating agents (ESAs), iron supplements, and addressing the underlying kidney condition to improve red blood cell levels and overall health. The market is experiencing transformative shifts, primarily driven by technological advancements in diagnostics and the development of new erythropoiesis-

stimulating agents (ESAs). The increasing prevalence of chronic kidney disease (CKD), coupled with growing awareness and early detection initiatives, is fueling the demand for renal anemia treatments.

The Key market drivers include the escalating burden of CKD, advancements in early detection and diagnosis, and the emergence of innovative therapies. There are significant opportunities for the development of non-ESA-based therapies, targeted drug delivery systems, and personalized treatment regimens. Additionally, the market is witnessing the emergence of biosimilars, offering cost-effective treatment options and expanding access to therapy. Regulatory approvals for novel therapies and the expansion of reimbursement policies are expected to further drive market growth. A major risk factor for developing renal anemia is chronic kidney disease. With the increase in CKD prevalence globally, the need for effective treatment options for renal anemia is expected to surge. According to the National Kidney Foundation, approximately 37 million adults in the United States have CKD, and this figure is expected to rise to 47 million by 2030. This rising incidence of CKD is a key driver of growth in the Global Renal Anemia Market.

The key region in the Global Renal Anemia Market includes North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. In 2023, North America is expected to hold the largest market share, due to its advanced healthcare infrastructure, high prevalence of chronic kidney disease, and strong emphasis on innovative treatments. The region benefits from robust research and development capabilities, leading to the introduction of advanced therapies and technologies for managing renal anemia. Additionally, a high rate of early diagnosis and a well-established market for pharmaceuticals and healthcare services contribute to North America's significant market share. The Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period 2024-2032. The growth in APAC is attributed to the increasing prevalence of chronic kidney disease and the rising demand for dialysis treatments in the region.

Major market players included in this report are:

Roche

AstraZeneca PLC

Fresenius Medical Care AG & Co. KGAA

Johnson & Johnson

Astellas Pharma Inc.

Amgen Inc.

Otsuka Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

Novartis AG  
AbbVie Inc.  
Sanofi  
Pfizer Inc.  
Baxter International Inc.  
DaVita Inc.

The detailed segments and sub-segments of the market are explained below:

By Anemia Type:

Iron Deficiency Anemia  
Vitamin B12 Deficiency Anemia  
Folate Deficiency Anemia  
Aplastic Anemia  
Hemolytic Anemia  
Sickle Cell Anemia

By Treatment Type:

Erythropoiesis-Stimulating Agents (ESAs)  
Iron Supplementation  
Vitamin B12 Supplementation  
Folate Supplementation  
Transfusion Therapy  
Bone Marrow Transplant

By Disease Severity:

Mild  
Moderate  
Severe

By End-User:

Hospitals  
Dialysis Centers  
Clinics  
Home Healthcare

By Route of Administration:

Intravenous  
Subcutaneous  
Oral

**By Region:**

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East &amp; Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates &amp; Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.  
Detailed analysis of geographical landscape with Country level analysis of major regions.  
Competitive landscape with information on major players in the market.  
Analysis of key business strategies and recommendations on future market approach.  
Analysis of competitive structure of the market.  
Demand side and supply side analysis of the market.

## Contents

### **CHAPTER 1. GLOBAL RENAL ANEMIA MARKET EXECUTIVE SUMMARY**

- 1.1. Global Renal Anemia Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Anemia Type
  - 1.3.2. By Treatment Type
  - 1.3.3. By Disease Severity
  - 1.3.4. By End-User
  - 1.3.5. By Route of Administration
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL RENAL ANEMIA MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Availability
    - 2.3.3.2. Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Consumer's Perspective)
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Regulatory Frameworks
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental Considerations
    - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

## **CHAPTER 3. GLOBAL RENAL ANEMIA MARKET DYNAMICS**

### 3.1. Market Drivers

- 3.1.1. Increasing Prevalence of Chronic Kidney Disease (CKD)
- 3.1.2. Growing Adoption of Erythropoiesis-Stimulating Agents (ESAs)
- 3.1.3. Rising Demand for Non-Invasive Treatment Options

### 3.2. Market Challenges

- 3.2.1. High Cost of Treatment
- 3.2.2. Side Effects Associated with ESAs

### 3.3. Market Opportunities

- 3.3.1. Development of Non-ESA-Based Therapies
- 3.3.2. Targeted Drug Delivery Systems
- 3.3.3. Personalized Treatment Regimens

## **CHAPTER 4. GLOBAL RENAL ANEMIA MARKET INDUSTRY ANALYSIS**

### 4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

### 4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### 4.3. Top Investment Opportunity

### 4.4. Top Winning Strategies

### 4.5. Disruptive Trends

### 4.6. Industry Expert Perspective

### 4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL RENAL ANEMIA MARKET SIZE & FORECASTS BY ANEMIA TYPE 2022-2032**

### 5.1. Segment Dashboard

### 5.2. Global Renal Anemia Market: Anemia Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 5.2.1. Iron Deficiency Anemia
- 5.2.2. Vitamin B12 Deficiency Anemia
- 5.2.3. Folate Deficiency Anemia
- 5.2.4. Aplastic Anemia
- 5.2.5. Hemolytic Anemia
- 5.2.6. Sickle Cell Anemia

## **CHAPTER 6. GLOBAL RENAL ANEMIA MARKET SIZE & FORECASTS BY TREATMENT TYPE 2022-2032**

### 6.1. Segment Dashboard

### 6.2. Global Renal Anemia Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 6.2.1. Erythropoiesis-Stimulating Agents (ESAs)
- 6.2.2. Iron Supplementation
- 6.2.3. Vitamin B12 Supplementation
- 6.2.4. Folate Supplementation
- 6.2.5. Transfusion Therapy
- 6.2.6. Bone Marrow Transplant

## **CHAPTER 7. GLOBAL RENAL ANEMIA MARKET SIZE & FORECASTS BY DISEASE SEVERITY 2022-2032**

### 7.1. Segment Dashboard

### 7.2. Global Renal Anemia Market: Disease Severity Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 7.2.1. Mild
- 7.2.2. Moderate
- 7.2.3. Severe

## **CHAPTER 8. GLOBAL RENAL ANEMIA MARKET SIZE & FORECASTS BY END-USER 2022-2032**

### 8.1. Segment Dashboard

### 8.2. Global Renal Anemia Market: End-User Revenue Trend Analysis, 2022 & 2032



(USD Billion)

- 8.2.1. Hospitals
- 8.2.2. Dialysis Centers
- 8.2.3. Clinics
- 8.2.4. Home Healthcare

## **CHAPTER 9. GLOBAL RENAL ANEMIA MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022-2032**

- 9.1. Segment Dashboard
- 9.2. Global Renal Anemia Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  - 9.2.1. Intravenous
  - 9.2.2. Subcutaneous
  - 9.2.3. Oral

## **CHAPTER 10. GLOBAL RENAL ANEMIA MARKET SIZE & FORECASTS BY REGION 2022-2032**

- 10.1. North America Renal Anemia Market
  - 10.1.1. U.S. Renal Anemia Market
    - 10.1.1.1. Anemia Type breakdown size & forecasts, 2022-2032
    - 10.1.1.2. Treatment Type breakdown size & forecasts, 2022-2032
    - 10.1.1.3. Disease Severity breakdown size & forecasts, 2022-2032
    - 10.1.1.4. End-User breakdown size & forecasts, 2022-2032
    - 10.1.1.5. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.1.2. Canada Renal Anemia Market
- 10.2. Europe Renal Anemia Market
  - 10.2.1. U.K. Renal Anemia Market
  - 10.2.2. Germany Renal Anemia Market
  - 10.2.3. France Renal Anemia Market
  - 10.2.4. Spain Renal Anemia Market
  - 10.2.5. Italy Renal Anemia Market
  - 10.2.6. Rest of Europe Renal Anemia Market
- 10.3. Asia-Pacific Renal Anemia Market
  - 10.3.1. China Renal Anemia Market
  - 10.3.2. India Renal Anemia Market
  - 10.3.3. Japan Renal Anemia Market
  - 10.3.4. Australia Renal Anemia Market

- 10.3.5. South Korea Renal Anemia Market
- 10.3.6. Rest of Asia Pacific Renal Anemia Market
- 10.4. Latin America Renal Anemia Market
  - 10.4.1. Brazil Renal Anemia Market
  - 10.4.2. Mexico Renal Anemia Market
  - 10.4.3. Rest of Latin America Renal Anemia Market
- 10.5. Middle East & Africa Renal Anemia Market
  - 10.5.1. Saudi Arabia Renal Anemia Market
  - 10.5.2. South Africa Renal Anemia Market
  - 10.5.3. Rest of Middle East & Africa Renal Anemia Market

## **CHAPTER 11. COMPETITIVE INTELLIGENCE**

- 11.1. Key Company SWOT Analysis
  - 11.1.1. Company
  - 11.1.2. Company
  - 11.1.3. Company
- 11.2. Top Market Strategies
- 11.3. Company Profiles
  - 11.3.1. Roche
    - 11.3.1.1. Key Information
    - 11.3.1.2. Overview
    - 11.3.1.3. Financial (Subject to Data Availability)
    - 11.3.1.4. Product Summary
    - 11.3.1.5. Market Strategies
  - 11.3.2. AstraZeneca PLC
  - 11.3.3. Fresenius Medical Care AG & Co. KGAA
  - 11.3.4. Johnson & Johnson
  - 11.3.5. Astellas Pharma Inc.
  - 11.3.6. Amgen Inc.
  - 11.3.7. Otsuka Pharmaceutical Co., Ltd.
  - 11.3.8. Merck & Co., Inc.
  - 11.3.9. Teva Pharmaceutical Industries Ltd.
  - 11.3.10. Novartis AG
  - 11.3.11. AbbVie Inc.
  - 11.3.12. Sanofi
  - 11.3.13. Pfizer Inc.
  - 11.3.14. Baxter International Inc.
  - 11.3.15. DaVita Inc.

## **CHAPTER 12. RESEARCH PROCESS**

### 12.1. Research Process

#### 12.1.1. Data Mining

#### 12.1.2. Analysis

#### 12.1.3. Market Estimation

#### 12.1.4. Validation

#### 12.1.5. Publishing

### 12.2. Research Attributes

## List Of Tables

### LIST OF TABLES

TABLE 1. Global Renal Anemia market, report scope

TABLE 2. Global Renal Anemia market estimates & forecasts by Region 2022-2032 (USD Billion)

TABLE 3. Global Renal Anemia market estimates & forecasts by Anemia Type 2022-2032 (USD Billion)

TABLE 4. Global Renal Anemia market estimates & forecasts by Treatment Type 2022-2032 (USD Billion)

TABLE 5. Global Renal Anemia market estimates & forecasts by Disease Severity 2022-2032 (USD Billion)

TABLE 6. Global Renal Anemia market estimates & forecasts by End-User 2022-2032 (USD Billion)

TABLE 7. Global Renal Anemia market estimates & forecasts by Route of Administration 2022-2032 (USD Billion)

TABLE 8. Global Renal Anemia market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 9. Global Renal Anemia market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 10. Global Renal Anemia market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 11. Global Renal Anemia market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 12. Global Renal Anemia market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 13. Global Renal Anemia market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 14. Global Renal Anemia market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 15. U.S. Renal Anemia market estimates & forecasts, 2022-2032 (USD Billion)

TABLE 16. U.S. Renal Anemia market estimates & forecasts by segment 2022-2032 (USD Billion)

TABLE 17. U.S. Renal Anemia market estimates & forecasts by segment 2022-2032 (USD Billion)

TABLE 18. Canada Renal Anemia market estimates & forecasts, 2022-2032 (USD Billion)

TABLE 19. Canada Renal Anemia market estimates & forecasts by segment 2022-2032

(USD Billion)

TABLE 20. Canada Renal Anemia market estimates & forecasts by segment 2022-2032

(USD Billion)

.....

This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.

## List Of Figures

### LIST OF FIGURES

- FIG 1. Global Renal Anemia market, research methodology
- FIG 2. Global Renal Anemia market, market estimation techniques
- FIG 3. Global market size estimates & forecast methods.
- FIG 4. Global Renal Anemia market, key trends 2023
- FIG 5. Global Renal Anemia market, growth prospects 2022-2032
- FIG 6. Global Renal Anemia market, porters 5 force model
- FIG 7. Global Renal Anemia market, PESTEL analysis
- FIG 8. Global Renal Anemia market, value chain analysis
- FIG 9. Global Renal Anemia market by segment, 2022 & 2032 (USD Billion)
- FIG 10. Global Renal Anemia market by segment, 2022 & 2032 (USD Billion)
- FIG 11. Global Renal Anemia market by segment, 2022 & 2032 (USD Billion)
- FIG 12. Global Renal Anemia market by segment, 2022 & 2032 (USD Billion)
- FIG 13. Global Renal Anemia market by segment, 2022 & 2032 (USD Billion)
- FIG 14. Global Renal Anemia market, regional snapshot 2022 & 2032
- FIG 15. North America Renal Anemia market 2022 & 2032 (USD Billion)
- FIG 16. Europe Renal Anemia market 2022 & 2032 (USD Billion)
- FIG 17. Asia pacific Renal Anemia market 2022 & 2032 (USD Billion)
- FIG 18. Latin America Renal Anemia market 2022 & 2032 (USD Billion)
- FIG 19. Middle East & Africa Renal Anemia market 2022 & 2032 (USD Billion)
- FIG 20. Global Renal Anemia market, company market share analysis (2023)

.....

This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.

## I would like to order

Product name: Global Renal Anemia Market Size Study, by Anemia Type (Iron Deficiency Anemia, Vitamin B12 Deficiency Anemia, Folate Deficiency Anemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia), by Treatment Type (Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation, Vitamin B12 Supplementation, Folate Supplementation, Transfusion Therapy, Bone Marrow Transplant), by Disease Severity (Mild, Moderate, Severe), by End-User (Hospitals, Dialysis Centers, Clinics, Home Healthcare), by Route of Administration (Intravenous, Subcutaneous, Oral) and Regional Forecasts 2024-2032

Product link: <https://marketpublishers.com/r/GAA5D341B494EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAA5D341B494EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970